10 results
424B3
IKT
Inhibikase Therapeutics Inc
4 Apr 23
Prospectus supplement
4:57pm
N=88)
Parkinson Patient Value
(% of total, N=25)
Gender
Female
Male
Age
Average (SD)
Median
Range
Ethnicity
Hispanic or Latino
Not Hispanic
POS AM
IKT
Inhibikase Therapeutics Inc
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
(% of Total N=88)
Parkinson Patient Value
(% of total, N=25)
Gender
Female
Male
Age
Average (SD)
Median
Range
Ethnicity
Hispanic or Latino
Not Hispanic
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
16 Sep 22
Regulation FD Disclosure
4:09pm
(57.2) Age Average (SD) 57.9 (5.72) 62.5 Median 58.0 62 Range 45, 69 57, 70 Ethnicity Hispanic or Latino 13 (14.8) 3 (23.1) Not Hispanic or Latino 75
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
15 Aug 22
Regulation FD Disclosure
5:12pm
IkT-148009 does not Range 45, 69 57, 70 lead to typical c-Abl Ethnicity Hispanic or Latino 13 (14.8) 3 (23.1) inhibitor adverse events: Not Hispanic
8-K
EX-99.1
sjackpd77vjxijod7r76
21 Apr 22
Regulation FD Disclosure
4:19pm
8-K
EX-99.1
252xmgy z4qwub
24 Mar 22
Regulation FD Disclosure
9:17am
8-K
EX-99.1
f17auu3uxo1qurz 39e
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
8-K
EX-99.1
kxzsgaan
19 Oct 21
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT
5:03pm
8-K
EX-99.1
hbajnb6l2f
17 Aug 21
Regulation FD Disclosure
5:02pm
- Prev
- 1
- Next